Czech Republic Pharmaceuticals and Healthcare Report Q2 2016

77 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: The Czech Republic will continue to be one of the most attractive markets in the CEE region for
pharmaceutical and healthcare investment. A strong economic outlook will be the driving factor behind
growth, with plans to further increase access to healthcare; pharmaceutical sales are expected to increase
over the coming years.
Headline Expenditure Projections
? Pharmaceuticals: CZK78.83bn (USD3.01bn) in 2015 to CZK81.10bn (USD3.27bn) in 2016; +2.9% in
local currency terms and +8.6 % in US dollar terms. Forecasts in line with last quarter.
? Healthcare: CZK284.72bn (USD10.87bn) in 2015 to CZK292.53bn (USD11.79bn) in 2016; +2.7% in
local currency terms and +8.4% in US dollar terms. Forecasts in line with last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Czech Republic 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2014-2020) 29
Table: Pharmaceutical Trade Data And Forecasts local currency (Czech Republic 2014-2020) 30
Industry Risk Reward Index 31
Central And Eastern Europe Risk/Reward Index - Q2 2016 31
Czech Republic - Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 38
Regulatory Regime 38
Pricing Regime 39
Reimbursement Regime 40
Table: European VAT Rates On Medicines (%) 43
Market Overview 46
Healthcare Sector 46
Table: Healthcare Resources (Czech Republic 2010-2015) 48
Table: Healthcare Personnel (Czech Republic 2010-2015) 48
Table: Healthcare Activity (Czech Republic 2010-2015) 49
Research & Development 52
Clinical Trials 53
Epidemiology 55
Competitive Landscape 58
Research-Based Industry 58
Table: Multinational Market Activity 58
Generic Drugmakers 59
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 60
Company Profile 62
Zentiva (Sanofi) 62
Demographic Data 66
Demographic Forecast 66
Table: Population Headline Indicators (Czech Republic 1990-2025) 67
Table: Key Population Ratios (Czech Republic 1990-2025) 67
Table: Urban/Rural Population & Life Expectancy (Czech Republic 1990-2025) 68
Table: Population By Age Group (Czech Republic 1990-2025) 68
Table: Population By Age Group % (Czech Republic 1990-2025) 69
Glossary 71
Methodology 73
Pharmaceutical Expenditure Forecast Model 73
Healthcare Expenditure Forecast Model 73
Notes On Methodology 74
Risk/Reward Index Methodology 75
Index Overview 76
Table: Pharmaceutical Risk/Reward Index Indicators 76
Indicator Weightings 77

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Czech Republic 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Czech Republic 2014-2020)
Table: European VAT Rates On Medicines (%)
Table: Healthcare Resources (Czech Republic 2010-2015)
Table: Healthcare Personnel (Czech Republic 2010-2015)
Table: Healthcare Activity (Czech Republic 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (Czech Republic 1990-2025)
Table: Key Population Ratios (Czech Republic 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Czech Republic 1990-2025)
Table: Population By Age Group (Czech Republic 1990-2025)
Table: Population By Age Group % (Czech Republic 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Serbia Pharmaceuticals and Healthcare Report Q2 2016BMI View: The Serbian pharmaceutical and healthcare market remains one of the least attractive within the CEE region for foreign drugmakers. Government cost containment, implemented through severe drug price cuts by the RFZO, will dampen growth. Furthermore, an increasing reliance on private health spending will impact pharmaceutical sales as the worsening macroeconomic outlook will reduce consumer spending power. Headline Expenditure Projections Pharmaceuticals: RSD91.42bn […]
  • Czech Republic Pharmaceuticals and Healthcare Report Q1 2016BMI View: The Czech Republic's pharmaceutical market will continue to stand as one of the more attractive to drugmakers in the Central and Eastern Europe region in the coming years. Strong economic expansion and healthcare sector growth fundamentals, including high underlying demand for healthcare and rising expenditure per capita, will underpin market expansion. Meanwhile, the broader European economic recovery will continue to act as a tailwind to high fixed investment rates in the […]
  • Gabon Pharmaceuticals and Healthcare Report Q2 2016BMI View: Gabon's small pharmaceutical market size will continue to discourage investment from multinational pharmaceutical companies. Over the long-term, the country's evolving demographic profile, boosts to domestic manufacturing capabilities, and the success of the national health insurance scheme will provide momentum for pharmaceutical expenditure. However questions will be asked over the financial sustainability of the national health insurance scheme. Cost-containment measures […]
  • Costa Rica Pharmaceuticals and Healthcare Report Q2 2016BMI View: Costa Rica's increasing demand for healthcare and improving regulatory regime will support its long-term pharmaceutical market growth. The relatively stable economic and political climate in Costa Rica will continue to provide a business friendly environment for pharmaceutical companies to invest in the local market. Headline Expenditure Projections Pharmaceuticals: CRC446.9bn (USD813mn) in 2015 to CRC469.5bn (USD861mn) in 2016; +5.0% in local currency terms and 6.0% in US […]
  • Czech Republic Pharmaceuticals and Healthcare Report Q2 2015BMI View: With recently implemented cost-saving measures, legislative changes, and health insurance reforms, the Czech Republic is set to recover from its recent period of stagnancy and decline. Indeed, these changes will help to provide for the growing demand for innovative drugs among the country's ageing population. The healthcare spending of the Czech population remains superior to that of the less-developed markets of Eastern and South Eastern Europe, demonstrating that demand […]